• Pfizer and Lilly receive FDA Fast Track designation for tanezumab worldpharmanews
    June 14, 2017
    Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chroni
PharmaSources Customer Service